yesterday announc deal combin upjohn
subsidiari overal given under-perform
last year period think clear
need someth chang direct myl stock
finish approxim yesterday vs
still ytd vs
last twelv month vs
thought earlier see
also report result yesterday reiter
previous issu guidanc report revenu
beat consensu estim miss
estim adjust ep came
consensu estim forecast
note portion bottom line beat driven slight
beat gross margin vs consensu
underspend quarter report adjust
 versu consensu estim
estim note underspend also
case report adjust vs
consensu adjust guidanc call
revenu year seem us
like fall low end guidanc
opinion commentari call instil
confid state thing promis go find
total stabil revenu ebitda free cash
flow seem hard fulfil given histori sector
note report last week frequent
highlight china sinc china seem like oz pharma
compani china mention approxim time call
yesterday given rapidli china drug reimburs plan
chang suspect sourc great opportun
potenti variabl futur
think better upjohn busi
busi re-domicil slightli deliv
sharehold promis dividend better govern
although think markedli differ
past high compens relat parti transact overhang
epipen price collus opioid litig etc
think integr risk especi ceo new
cultur limit experi gener think
investor like new combin slightli
old mylan chang better updat
model earn price target increas modestli
account roll dcf forward mid-year mark
maintain market perform rate
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
report non-gaap ep exclud one-tim item includ restructur
compani data secur llc estim reuter
us announc upjohn deal seem similar posit abbott deal
approxim five year ago accord transcript confer call held describ
transact complement exist strategi hit mani key driver
transact allow us leverag busi global across channel effect
custom particularli light continu consolid custom
global basi also becom even attract partner given broad portfolio
high qualiti effici vertic integr manufactur platform suppli chain
think perfect fit one major differenti point acquir
specialti brand gener busi collect product includ commerci
manufactur infrastructur market alreadi establish distinct
interest grow transact ad employe
mention undertaken number deal past sever year mani
describ immedi accret may help better weather
gener drug price contract recent year note miss previou consensu
estim earn target
overal consid overli disappoint especi strong vs expect
exhibit result vs estim consensu mm except per share
compani report factset secur llc estim
exhibit guidanc vs wf current consensu mm except per share
compani report factset secur llc estim
factset consensuswel fargo secur estim /- wf estimate north incom highmidpointwf estimate consensustot gross sg net
factset secur llc estim
million unless otherwis note
compani report secur llc estim
incom profit expens expens interest incom incom incom per
price target
dcf-deriv price target base discount rate termin ev/ebitda multipl
risk includ gener drug market dynam like continu challeng
gener drug penetr may alreadi peak epipen concentr sale profit
govern risk sec investig lawsuit integr risk tie meda deal
rate base expect outperform back-end load
structur issu remain gener combin upjohn posit
integr base gener busi risk remain remain sidelin get
evid signific chang gener hit set expect consist
els equal
mylan inc base canonsburg pa domicil netherland among world
largest gener pharmaceut compani engag develop licens manufactur
market distribut gener proprietari pharmaceut product primari specialti
pharma product epipen treatment acut allerg reaction
